Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial-Reference-Cited by-同舟云学术

Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial

Published:2019-05-25 Issue:8 Volume:8 Page:e1614857
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ji Niannian¹,Mukherjee Neelam¹,Morales Edwin E.¹,Tomasini Maggie E.¹,Hurez Vincent²,Curiel Tyler J.²,Abate Getahun³,Hoft Dan F.³,Zhao Xiang-Ru²,Gelfond Jon⁴,Maiti Sourindra⁵,Cooper Laurence J.N.⁵,Svatek Robert S.¹

Affiliation:

1. Department of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA

2. Department of Medicine/Hematology & Medical Oncology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA

3. Department of Internal Medicine, Division of Infectious Diseases, Allergy and Immunology, Saint Louis University Edward A. Doisy Research Center, .St. Louis, MO, USA

4. Department of Epidemiology and Biostatistics, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA

5. Pediatrics, M.D. Anderson Cancer Center, Houston, TX, USA

Funder

Bladder Cancer Advocacy Network

Cancer Prevention and Research Institute of Texas

Max and Minnie Tomerlin Voelcker Fund

National Institutes of Health

The Roger L. and Laura D. Zeller Charitable Foundation Chair in Urologic Cancer

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy